American Heart Association Scientific Sessions 2019
The Medicines Company is proud to showcase our participation in the American Heart Association (AHA) Scientific Sessions in Philadelphia. We are honored to work with the cardiology community to overcome the greatest global healthcare challenge and burden today – cardiovascular disease – and address a leading risk factor – cumulative exposure to LDL-C.
Visit The Medicines Company at booth #2001 to talk with our team about the impact of cumulative exposure to LDL-C, use our interactive map to find out how many ASCVD patients are at LDL-C goal in each U.S. state, and complete a short survey.
The Medicines Company Scientific Agenda
Late-breaking Science Sessions
Safety and efficacy of inclisiran in patients with ASCVD and elevated LDL cholesterol: Results from the Phase 3 ORION-10 trial
Saturday, November 16: 11:06–11:14 AM
Main Event I
Safety and efficacy of inclisiran in patients with heterozygous familial hypercholesterolemia: Results from the Phase 3 ORION-9 trial
Monday, November 18: 9:24–9:32 AM
Main Event I
Health Innovation Pavilion
siRNA and gene silencing: What clinicians should know about a new class of medications
Saturday, November 16: 10:00–10:30 AM
Science and Technology Hall
Emerging concepts in LDL-C: Can we alter the course of ASCVD?
Sunday, November 17: 6:30 PM registration, 7:00–8:00 PM program, 8:00 PM seated dinner
Westin Philadelphia: 99 South 17th Street at Liberty Place, Philadelphia, PA 19103
Grand Ballroom Salons I-III - Lobby Level, 3rd Floor
Cardiovascular Expert Theater
Adherence: Is it really intractable?
Monday, November 18: 10:15–11:00 AM
Learning Studio 2, Booth 7, Science and Technology Hall
The Medicines Company is also proud to sponsor accredited CME programming.